AstraZeneca has sector leading replacement power to cope with 2030 patent cliff
The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS,...…
92,830$
0,26%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Arcus (RCUS) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DATEWednesday, Feb. 25, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Terry J. RosenPresident —…
IonQ (IONQ) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.DateFeb. 25, 2026 at 4:30 p.m. ETCall participantsChairman and Chief Executive Officer — Niccolo de MasiChief…
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
AZNs stronger growth outlook and 2030 revenue target may outshine PFEs yield and cheaper valuation.…
Fixed-duration Calquence combo approved in US
20 February 2026Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in…
Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor
In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal…
Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor
In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal…
Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer
Lund, Sweden — 17 February 2026 — Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed…
Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus
…
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory
Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to hold from buy, citing a less favourable earnings trajectory as the drugmaker...…
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory
Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to hold from buy, citing a less favourable earnings trajectory as the drugmaker...…
Citi maintains buy on AstraZeneca with £170 target, cites sector-best pipeline
Double-digit earnings outlook and strong trial momentum support top pick status AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a top pick at…
Citi maintains buy on AstraZeneca with £170 target, cites sector-best pipeline
Double-digit earnings outlook and strong trial momentum support top pick status AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a top pick at…
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
…
Heres What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended December 2025, but…
US-UK pharma deal isn’t enough to get AstraZeneca investing in Britain again
LONDON — AstraZeneca CEO Pascal Soriot says the pharmaceutical giant is still not ready to restart its paused U.K. investments,…
AstraZeneca’s growth engine stays on track despite cost pressures
AstraZeneca PLCs (LSE:AZN, NASDAQ:AZN) full-year results showed the pharmaceutical group navigating a challenging comparison period with a robust...…
FTSE 100 slips as Standard Chartered and BP weigh
The FTSE 100 slipped on Tuesday as investors digested a raft of corporate updates from companies including Barclays, AstraZeneca, and…
KORREKTUR/ROUNDUP: Astrazeneca will 2026 mehr verdienen - Aktie nahe Rekordhoch
(Es wird in der Überschrift und im 1. Absatz klargestellt, dass die Aktie sich ihrem Rekordhoch genähert rpt genähert hat.)…
ROUNDUP: Astrazeneca will auch 2026 mehr verdienen - Aktie auf Rekordhoch
CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca stellt sich nach einem schwungvollen Jahr auf weiteres Wachstum ein und will zugleich…